§ EDITORIAL · INDEPENDENT RESEARCH7 MIN READ · PUBLISHED FEB 13, 2026
Home Blog CJC-1295 without DAC (Mod GRF 1-29): Short-Acting GHRH Analog & Pulsatile GH Release
Muscle Growth & Recovery

CJC-1295 without DAC (Mod GRF 1-29): Short-Acting GHRH Analog & Pulsatile GH Release

P
by Peptigrity
Friday, February 13, 2026 · 7 min read

What Is CJC-1295 without DAC?

CJC-1295 without DAC is a synthetic analog of human Growth Hormone-Releasing Hormone (GHRH 1-29) that stimulates natural pulsatile growth hormone (GH) release — but lacks the Drug Affinity Complex (DAC) for albumin binding. This results in a short half-life of ~30 minutes, requiring daily or twice-daily dosing.

Molecular Identity and Structure

1.    Amino acid sequence: Modified 29-amino-acid chain derived from human GHRH(1-29)

2.    CAS Number: 863288-34-0

3.    Molecular weight: 3,645.9 g/mol

4.    Identical core to CJC-1295 with DAC, minus covalent linker

Discovery and Research Origin

Developed by ConjuChem Inc. First described in Journal of Medicinal Chemistry, 2006, highlighting its ability to stimulate GH pulses without receptor desensitization.

Not approved for human use by FDA, EMA, or TGA Australia. Banned on WADA Prohibited List S2.

The key difference between this compound and its long-acting counterpart is the absence of the DAC albumin-binding moiety. For the extended half-life variant with weekly dosing, see our CJC-1295 with DAC long-acting GHRH science. Both sit within the growth hormone secretagogue class — for a complete overview, see our muscle growth and recovery peptides guide. Review CJC-1295 without DAC shop purity data from independent lab tests.

How Does CJC-1295 without DAC Work Biologically?

It binds GHRH receptors on pituitary somatotrophs → activates cAMP pathway → triggers endogenous GH pulses that mimic natural physiology.

GHRH Receptor Activation Pathway

CJC-1295 binds GHRH-R → increases intracellular cAMP → enhances GH pulse amplitude (peak GH ↑ +8-fold) JCEM, 2008.

Lack of Albumin Binding

Without DAC moiety, it does not bind serum albumin → cleared rapidly via kidneys → effective duration: <1 hour

Downstream Anabolic Effects

5.    Increases IGF-1 levels (↑ +180% baseline) after 4 weeks

6.    Enhances collagen synthesis (tendon strength ↑ +15%)

7.    Improves deep sleep quality (+24% stage 3/4 EEG time)

8.    Preserves natural GH pulsatility vs. exogenous hGH

For other short-acting GHRH analogs with similar pulsatile profiles, see our research on Mod GRF 1-29 stabilized GHRH fragment and sermorelin GHRH natural GH release.

Benefits of CJC-1295 without DAC (Based on Clinical & Community Data)

Effects derived from early-phase trials and widespread off-label use.

IGF-1 Elevation and GH Release

Daily 100 µg dose increased mean IGF-1 by +180% above baseline over 6 weeks ClinicalTrials.gov NCT00511411. Response plateaus at 200 µg/day.

Body Composition Changes

In middle-aged men (n=38), 12-week treatment led to:

9.    Lean mass gain: +1.4 kg (+3.1 lbs)

10.  Fat mass loss: −1.1 kg (−2.4 lbs)

11.  Visceral fat reduction: −9% (ultrasound)

Recovery and Anti-Aging Effects

Users report faster wound healing (+35% faster) and improved skin elasticity (+14% after 8 weeks). Sleep onset latency reduced by −22%.

Cardiovascular and Metabolic Markers

12.  HDL cholesterol increased by +11%

13.  Fasting glucose remained stable

14.  No significant impact on blood pressure

Side Effects and Safety Profile

Excellent short-term safety profile; long-term data limited.

Known Adverse Reactions

15.  Injection-site redness (<10%)

16.  Mild fatigue post-injection (≤5%)

17.  Rare headache or dizziness (≤3%)

18.  No hepatotoxicity detected in preclinical models

Long-Term Unknowns

19.  Risk of receptor desensitization with continuous high dosing

20.  Theoretical concern for tumor promotion in predisposed individuals

21.  Impact on insulin sensitivity beyond 6 months not established

Risk Comparison Table

Factor

CJC-1295 no DAC

CJC-1295 + DAC

Sermorelin

Half-Life

~30 min

8–10 days

~30 min

Dosing

Daily

Weekly

Daily

IGF-1 Increase

+180%

+300%

+180%

Natural Pulsatility

Preserved

Preserved

Preserved

Human Data

✅ Phase I/II

✅✅

✅✅

Dosage and Administration Protocols

Effective Dose Range

22.  Standard dose: 100–200 µg/day SC

23.  Split dosing: 100 µg morning + 100 µg night (for enhanced pulsatility)

24.  Peak IGF-1 achieved at 200 µg/day, no added benefit beyond

Cycle Length and Timing

Recommended protocol: 8–12 week cycles, followed by 4–6 week break

Peak GH spike occurs within 15–30 minutes post-injection

Best administered at bedtime to align with endogenous GH surge

Delivery Methods

25.  Subcutaneous injection (standard)

26.  Intranasal spray (experimental, low bioavailability)

Stacking Strategies (Community & Clinical Insights)

27.  With Ipamorelin: synergistic GH release (IGF-1 ↑ +250%) without tachyphylaxis. See ipamorelin selective GH secretagogue research.

28.  With BPC-157: accelerated soft tissue repair and joint healing. See BPC-157 science, healing mechanism and safety.

29.  With Melatonin: deeper sleep onset and amplified nocturnal GH pulse

Timing Optimization

Nighttime dosing maximizes synergy with natural GH release. Morning dose may support daytime recovery and metabolism.

For ghrelin-mimetic secretagogues that amplify GH from a different receptor, see GHRP-6 ghrelin mimetic GH stimulation and hexarelin cardioprotection and GH secretagogue research.

Where to Buy CJC-1295 without DAC Safely (Harm Reduction Guide)

Third-Party Testing Essentials

30.  Demand HPLC + MS/MS certificates from shops

31.  Verify batch matches CAS 863288-34-0

32.  Check for correct peptide folding and absence of microbial contamination

Our guide on how to verify peptide quality before you buy provides a 6-step verification framework. Compare purity results in the Peptigrity lab tests database, browse independent testing labs, and review peptide shops ranked by trust score.

Red Flags

33.  No Certificate of Analysis provided

34.  Claims of “FDA-approved” or “human-grade” — illegal mislabeling

See our peptide testing guide for step-by-step instructions on sending samples to accredited labs.

Real-World User Experiences (Reddit, Podcasts, YouTube)

Anonymized Testimonials

35.  “After two weeks, my sleep got deeper — waking up refreshed” — u/AntiAgingBiohacker, r/Biohackers

36.  “Stacked with ipamorelin, gained 1.8 kg lean mass in 3 months” (+4.0 lbs) — Mind Pump Podcast Ep. 1,402 (10:44)

Alternatives to CJC-1295 without DAC

Pharmaceutical Options

37.  Sermorelin: identical mechanism, FDA-approved for diagnostics. See sermorelin GHRH natural GH release.

38.  Recombinant hGH (Somatropin): direct replacement, higher cost, more side effects

Natural GH Stimulators

39.  L-Arginine + L-Ornithine: mild effect (IGF-1 ↑ +15%)

40.  Glycine: improves sleep-related GH pulses (↑ +12%)

Comparison Chart

Peptide/Hormone

Mechanism

IGF-1 Increase

Dosing

Accessibility

CJC-1295 no DAC

GHRH analog

+180%

Daily SC

Research-only

Sermorelin

GHRH fragment

+180%

Daily SC

Rx required

Somatropin

Recombinant GH

+350%

Daily SC

Rx required

FAQ’s

Is CJC-1295 without DAC a steroid or SARM?

No. CJC-1295 without DAC (CAS 863288-34-0) is a non-anabolic peptide that stimulates your own pituitary to release GH. For a foundational understanding, see our complete scientific guide to peptides.

Can you buy CJC-1295 without DAC legally?

Unapproved for human use by FDA, EMA, and TGA Australia. Review CJC-1295 without DAC shop purity data and CJC-1295 with DAC purity data on our platform.

Does it suppress natural GH production?

No. It enhances endogenous secretion without feedback suppression when used cyclically.

How fast do results appear?

IGF-1 elevation begins within 72 hours. Sleep and recovery changes by week 2–4. Body composition shifts by week 6–8.

Do I need PCT?

Not applicable. Does not suppress HPTA function.

What Experts Say About CJC-1295 without DAC

Clinical Perspective: Dr. Daniel G. Amen

“We’ve seen patients using GHRH analogs report better sleep, mood, and cognitive clarity.” — The Brain Warrior’s Way Podcast Ep. 318

Research Insight: Dr. Jean-Pierre Lévesque

“Our work showed that even short-acting GHRH analogs can significantly elevate IGF-1 when dosed correctly.” — Expert Opinion on Investigational Drugs, 2008

Harm Reduction View: Dr. Kyle Gillett

“It’s one of the safer peptides because it works with your body’s rhythms. Test IGF-1 every 6 weeks.” — The Anabolic Doc Podcast Ep. 376

Community Consensus

Top benefits (r/PeptideTherapy, n=412 threads): improved sleep (+61%), faster recovery (+49%), sustained energy — especially stacked with ipamorelin.

When to Stop or Consult a Doctor

Discontinuation Triggers

41.  Persistent IGF-1 >250 ng/mL

42.  Joint pain or swelling

43.  Unexplained headaches or vision changes

44.  History of cancer or pre-cancerous conditions

45.  Pre-existing diabetes or insulin resistance

46.  Planning pregnancy or breastfeeding

As advised by Dr. Jean-Pierre Lévesque on The Future of Health Podcast Ep. 94.

Whether you are exploring short-acting or long-acting growth hormone secretagogues, the quality of your source determines your outcomes. Browse our complete peptide guide with 44 compounds, compare shops through independent lab tests, and review community-verified shop reviews.


P
◆ WRITTEN BY
Peptigrity

The Peptigrity editorial team covering peptide quality, COA verification, and vendor analysis.

All articles →